Clinical Management With SPM System and Validation of the SPM 5 Hour Cutoff in Patients With Symptoms of Gastroparesis

Inclusion Criteria: * Males and females between ages of 18-80 years of age with symptoms of gastroparesis for at least 12 weeks. * Presenting with 2 or more of the following symptoms or signs which, in the opinion of the site investigator, are suggestive of a diagnosis of gastroparesis: * 1 Nausea, vomiting, or retching (dry heaves) * 2 Postprandial fullness or early satiety * 3 Bloating or visible abdominal distention * 4 Postprandial discomfort or pain * Ability to stop proton pump inhibitors for 7 days and histamine2 receptor antagonists, prokinetic agents, narcotic agents, anticholinergic drugs, and cannabinoids 3 days prior to SPM and gastric scintigraphy testing. * No evidence of metabolic disease (hypothyroidism, uncontrolled diabetes \[hemoglobin A1c \>10% within the past 6 months\], electrolyte imbalance). * An upper endoscopy or upper gastrointestinal barium series within the past 2 years showing no organic disease that is potentially causative of symptoms. * High probability of compliance and completion of study. Exclusion Criteria: * Participation in previous SmartPill clinical trials. * Previous history of bezoars (the presence of retained liquid, bile, or small amounts of poorly organized food residue is permitted). * Dysphagia to solid food or pills. * Prior surgery involving the luminal gastrointestinal tract (cholecystectomy, appendectomy, and hysterectomy are permitted if performed \> 3 months prior to SPM test). * Any abdominal or pelvic surgery within the past 3 months * Known or history of inflammatory bowel disease. * History of diverticulitis, diverticular stricture, and other intestinal strictures. * Chronic daily use of nonsteroidal anti-inflammatory drugs (ibuprofen, naproxen, etc.) * Tobacco or alcohol use within eight hours prior to capsule ingestion. * BMI \> 40 kg/m2. * Allergies to eggs, bread, or jam. * Females of childbearing age who are not practicing birth control and/or are pregnant or lactating. (Urine pregnancy testing will be performed on female subjects of child-bearing potential prior to capsule ingestion and gastric scintigraphy). * Use of cardiac medical devices such as pacemakers and defibrillators (gastric stimulators, bladder stimulators, spinal stimulators, medication infusion devices, insulin pumps, continuous glucose monitors are permitted). * Uncontrolled diabetes with a hemoglobin A1c \>10%. * Patient is expected to undergo MRI examination within 7 days after ingestion of the capsule